BioSpace News Archive

Agendia announces new data published today in JAMA Oncology that demonstrate the benefits of the MammaPrint 70-Gene Breast Cancer Risk-of-Recurrence test to significantly change treatment management decisions for patients who had previously received an ‘intermediate’ risk result according to the 21-gene assay.

Oncoquest today announced the signing of a collaborative agreement with TESARO to conduct a proof-of-concept clinical trial evaluating the combination of oregovomab with ZEJULA (niraparib) in the recurrent ovarian cancer setting.

The first patient in Japan was treated with the Impella 5.0 heart pump after suffering from acute heart failure.

Up to 30 patients will be recruited in total from the United States and Israeli trial sites.

The Company will host a conference call to discuss the results on Thursday, October 26, 2017, at 8:00 a.m. EDT.

The Company has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock

The call can be accessed by dialing 1-844-309-0618 (U.S. and Canada) or 1-661-378-9465 (international).

The company’s CMO will leave, effective November 4, 2017 to pursue a new opportunity.

Analytical Lab Group has recently completed an expansion of its laboratories by acquiring Microbiology & Quality Associates in the San-Francisco Bay area.

Nine out of a planned ten adult patients with Prader-Willi syndrome have completed or discontinued from the Phase 2 study.